Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (1905)	10/23/2003 1:02:20 AM
From: Mike	Read Replies (1) \| Respond to of 3044

Irwin, Thanks for the post. I have been watching both MLNM and MDCO closely. I have been very impressed with MLNM's results that were just announced. I personally thought that Integrilin sales were going to drop substantially. It is quite impressive what MLNM's mgmt has been able to pull off. Here's my points. First Angiomax is hurting sales of Integrilin. But because of the additional 75 people that MLNM has put on the street to sell Integrilin they have been able to blunt the loss. MLNM actually had a $2.2MM increase in sales during the most recent qtr. This is impressive. I know it's nothing to run around and bang a drum but I will willing admit that I expected a shortfall. So the addition of these 75 reps currently I think has paid off well for MLNM. We will have to see the numbers for the fourth qtr for both MDCO and MLNM. Remember MDCO's success or failure is not soley dependant on the "failure" of MLNM. MDCO and Angiomax are trying to replace Heparin. Remember I know "marketing wise" MDCO is telling a different story. But I wanted to make sure to admit my mistake and incorrect assumption for the past qtr for MLNM would show a short fall in Integrilin sales. They have done a very nice job and the ACS market is where MLNM have picked up business. Congrats, Mike